메뉴 건너뛰기




Volumn 32, Issue 4, 2013, Pages e155-e163

Improved Vancomycin Dosing in Children Using Area Under the Curve Exposure

Author keywords

Antibiotic; Children; Pediatrics; Pharmacodynamic; Pharmacokinetic; Staphylococcus aureus; Vancomycin

Indexed keywords

CREATININE; VANCOMYCIN;

EID: 84876295339     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e318286378e     Document Type: Review
Times cited : (208)

References (23)
  • 1
    • 66949138112 scopus 로고    scopus 로고
    • Trends in the incidence of methicillin-resistant Staphylococcus aureus infection in childrens hospitals in the United States.
    • Gerber JS, Coffin SE, Smathers SA, et al. Trends in the incidence of methicillin-resistant Staphylococcus aureus infection in children’s hospitals in the United States. Clin Infect Dis. 2009;49:65-71
    • (2009) Clin Infect Dis , vol.49 , pp. 65-71
    • Gerber, J.S.1    Coffin, S.E.2    Smathers, S.A.3
  • 2
    • 79951821210 scopus 로고    scopus 로고
    • Infectious Diseases Society of America. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children.
    • Liu C, Bayer A, Cosgrove SE, et al.Infectious Diseases Society of America. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011;52:e18-e55
    • (2011) Clin Infect Dis , vol.52
    • Liu, C.1    Bayer, A.2    Cosgrove, S.E.3
  • 3
    • 77749255891 scopus 로고    scopus 로고
    • Clinical characteristics, outcomes, and microbiologic features associated with methicillin-resistant Staphylococcus aureus bacteremia in pediatric patients treated with vancomycin.
    • Welsh KJ, Abbott AN, Lewis EM, et al. Clinical characteristics, outcomes, and microbiologic features associated with methicillin-resistant Staphylococcus aureus bacteremia in pediatric patients treated with vancomycin. J Clin Microbiol. 2010;48:894-899
    • (2010) J Clin Microbiol , vol.48 , pp. 894-899
    • Welsh, K.J.1    Abbott, A.N.2    Lewis, E.M.3
  • 4
    • 62449183879 scopus 로고    scopus 로고
    • Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists.
    • Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm. 2009;66:82-98
    • (2009) Am J Health Syst Pharm , vol.66 , pp. 82-98
    • Rybak, M.1    Lomaestro, B.2    Rotschafer, J.C.3
  • 5
    • 79953907324 scopus 로고    scopus 로고
    • Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets.
    • Kullar R, Davis SL, Levine DP, et al. Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets. Clin Infect Dis. 2011;52:975-981
    • (2011) Clin Infect Dis , vol.52 , pp. 975-981
    • Kullar, R.1    Davis, S.L.2    Levine, D.P.3
  • 6
    • 79957606863 scopus 로고    scopus 로고
    • Eiland LS, English TM, Eiland EH 3rd. Assessment of vancomycin dosing and subsequent serum concentrations in pediatric patients. Ann Pharmacother. 2011;45:582-589
    • Eiland LS, English TM, Eiland EH 3rd. Assessment of vancomycin dosing and subsequent serum concentrations in pediatric patients. Ann Pharmacother. 2011;45:582-589
  • 7
    • 67649543995 scopus 로고    scopus 로고
    • Current recommended dosing of vancomycin for children with invasive methicillin-resistant Staphylococcus aureus infections is inadequate.
    • Frymoyer A, Hersh AL, Benet LZ, et al. Current recommended dosing of vancomycin for children with invasive methicillin-resistant Staphylococcus aureus infections is inadequate. Pediatr Infect Dis J. 2009;28:398-402
    • (2009) Pediatr Infect Dis J , vol.28 , pp. 398-402
    • Frymoyer, A.1    Hersh, A.L.2    Benet, L.Z.3
  • 8
    • 77951899851 scopus 로고    scopus 로고
    • Prediction of vancomycin pharmacodynamics in children with invasive methicillin-resistant Staphylococcus aureus infections: a Monte Carlo simulation.
    • Frymoyer A, Hersh AL, Coralic Z, et al. Prediction of vancomycin pharmacodynamics in children with invasive methicillin-resistant Staphylococcus aureus infections: a Monte Carlo simulation. Clin Ther. 2010;32:534-542
    • (2010) Clin Ther , vol.32 , pp. 534-542
    • Frymoyer, A.1    Hersh, A.L.2    Coralic, Z.3
  • 9
    • 33750344295 scopus 로고    scopus 로고
    • Population clinical pharmacology of children: modelling covariate effects.
    • Anderson BJ, Allegaert K, Holford NH. Population clinical pharmacology of children: modelling covariate effects. Eur J Pediatr. 2006;165:819-829
    • (2006) Eur J Pediatr , vol.165 , pp. 819-829
    • Anderson, B.J.1    Allegaert, K.2    Holford, N.H.3
  • 10
    • 83455171788 scopus 로고    scopus 로고
    • Vancomycin: a review of population pharmacokinetic analyses.
    • Marsot A, Boulamery A, Bruguerolle B, et al. Vancomycin: a review of population pharmacokinetic analyses. Clin Pharmacokinet. 2012;51:1-13
    • (2012) Clin Pharmacokinet , vol.51 , pp. 1-13
    • Marsot, A.1    Boulamery, A.2    Bruguerolle, B.3
  • 11
    • 0029145482 scopus 로고
    • Influence of malignancy on the pharmacokinetics of vancomycin in infants and children.
    • Chang D. Influence of malignancy on the pharmacokinetics of vancomycin in infants and children. Pediatr Infect Dis J. 1995;14:667-673
    • (1995) Pediatr Infect Dis J , vol.14 , pp. 667-673
    • Chang, D.1
  • 12
    • 0028125336 scopus 로고
    • A prospective study of vancomycin pharmacokinetics and dosage requirements in pediatric cancer patients.
    • Chang D, Liem L, Malogolowkin M. A prospective study of vancomycin pharmacokinetics and dosage requirements in pediatric cancer patients. Pediatr Infect Dis J. 1994;13:969-974
    • (1994) Pediatr Infect Dis J , vol.13 , pp. 969-974
    • Chang, D.1    Liem, L.2    Malogolowkin, M.3
  • 13
    • 0031836683 scopus 로고    scopus 로고
    • Pharmacokinetic analysis of vancomycin in steady state in pediatric cancer patients.
    • Krivoy N, Peleg S, Postovsky S, et al. Pharmacokinetic analysis of vancomycin in steady state in pediatric cancer patients. Pediatr Hematol Oncol. 1998;15:333-338
    • (1998) Pediatr Hematol Oncol , vol.15 , pp. 333-338
    • Krivoy, N.1    Peleg, S.2    Postovsky, S.3
  • 14
    • 0033958126 scopus 로고    scopus 로고
    • A population pharmacokinetic model for vancomycin in pediatric patients and its predictive value in a naive population.
    • Lamarre P, Lebel D, Ducharme MP. A population pharmacokinetic model for vancomycin in pediatric patients and its predictive value in a naive population. Antimicrob Agents Chemother. 2000;44:278-282
    • (2000) Antimicrob Agents Chemother , vol.44 , pp. 278-282
    • Lamarre, P.1    Lebel, D.2    Ducharme, M.P.3
  • 15
    • 0033806739 scopus 로고    scopus 로고
    • Vancomycin pharmacokinetics and Bayesian estimation in pediatric patients.
    • Wrishko RE, Levine M, Khoo D, et al. Vancomycin pharmacokinetics and Bayesian estimation in pediatric patients. Ther Drug Monit. 2000;22:522-531
    • (2000) Ther Drug Monit , vol.22 , pp. 522-531
    • Wrishko, R.E.1    Levine, M.2    Khoo, D.3
  • 16
    • 81155127325 scopus 로고    scopus 로고
    • Vancomycin pharmacokinetic-pharmacodynamic parameters to optimize dosage administration in critically ill children.
    • Giachetto GA, Telechea HM, Speranza N, et al. Vancomycin pharmacokinetic-pharmacodynamic parameters to optimize dosage administration in critically ill children. Pediatr Crit Care Med. 2011;12:e250-e254
    • (2011) Pediatr Crit Care Med , vol.12
    • Giachetto, G.A.1    Telechea, H.M.2    Speranza, N.3
  • 17
    • 0031756964 scopus 로고    scopus 로고
    • Therapeutic monitoring of vancomycin according to initial dosing regimen in pediatric patients.
    • Yasuhara M, Iga T, Zenda H, et al. Population pharmacokinetics of vancomycin in Japanese pediatric patients. Ther Drug Monit. 1998;20:612-618
    • (1998) Ther Drug Monit , vol.20 , pp. 612-618
    • Yasuhara, M.1    Iga, T.2    Zenda, H.3
  • 18
    • 68949123219 scopus 로고    scopus 로고
    • An assessment of vancomycin pharmacokinetic variability in pediatric cardiology patients
    • Marlowe KF, Chicella MF, Claridge TE, et al. An assessment of vancomycin pharmacokinetic variability in pediatric cardiology patients. J Pediatr Pharmacol Ther. 2003;8:132-136
    • (2003) J Pediatr Pharmacol Ther , vol.8 , pp. 132-136
    • Marlowe, K.F.1    Chicella, M.F.2    Claridge, T.E.3
  • 19
  • 21
    • 79951804452 scopus 로고    scopus 로고
    • Therapeutic monitoring of vancomycin according to initial dosing regimen in pediatric patients
    • Kim DI, Im MS, Choi JH, et al. Therapeutic monitoring of vancomycin according to initial dosing regimen in pediatric patients. Korean J Pediatr. 2010;53:1000-1005
    • (2010) Korean J Pediatr , vol.53 , pp. 1000-1005
    • Kim, D.I.1    Im, M.S.2    Choi, J.H.3
  • 22
    • 79951579705 scopus 로고    scopus 로고
    • Incidence and risk factors influencing the development of vancomycin nephrotoxicity in children.
    • McKamy S, Hernandez E, Jahng M, et al. Incidence and risk factors influencing the development of vancomycin nephrotoxicity in children. J Pediatr. 2011;158:422-426
    • (2011) J Pediatr , vol.158 , pp. 422-426
    • McKamy, S.1    Hernandez, E.2    Jahng, M.3
  • 23
    • 84860236045 scopus 로고    scopus 로고
    • Defining risk factors for red man syndrome in children and adults.
    • Myers AL, Gaedigk A, Dai H, et al. Defining risk factors for red man syndrome in children and adults. Pediatr Infect Dis J. 2012;31:464-468
    • (2012) Pediatr Infect Dis J , vol.31 , pp. 464-468
    • Myers, A.L.1    Gaedigk, A.2    Dai, H.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.